More Screening Needed Before Non-Cardiac Surgery

According to this recent document by the American Heart Association (AHA), troponin should be monitored for at least 3 days after surgery.

Más screening es necesario previo a una cirugía cardíaca

With about 20% of patients (most of them, asymptomatic) showing elevated troponin after a non-cardiac surgery, this new AHA document recommends monitoring, for at least two days, patients with moderate to severe ischemia.

Myocardial injury after non-cardiac surgery was first associated with increased mortality in 2014. At the time, researchers interpreted that these events could be triggered by an increased burden of risk factors, including patients over 75 years of age with sleep apnea, anemia, cardiac failure, diabetes, and hypertension.

The moral of this work would be that myocardial injury after non-cardiac surgery is frequent, silent, and fatal—so it should be taken into account.

Current evidence shows that patients who develop injury have four times higher 30-day mortality, and about 90% of this population has no identifiable symptoms.

Given that most subjects develop symptoms within 24 hours, the document suggests dosing troponins for 48 to 72 hours in patients at moderately high risk.


Read also: Hypertensive Patients: Maximizing Doses or Adding New Drugs.


The idea of performing ischemia-evoking tests prior to non-cardiac surgery left us without much to do if a patient with normal results developed an injury. Now we can comprehend the elevation and re-stratify patients, reducing their future risk.

Post-surgical injury should end in a direct referral to a cardiologist to evaluate the indication for aspirin and lifestyle changes. Patient could interpret this as secondary prevention.

CIR-0000000000001024

Original Title: Diagnosis and management of patients with myocardial injury after noncardiac surgery: a scientific statement from the American Heart Association.

Reference: Kurt Ruetzler et al. Circulation. 2021 Oct 4;CIR0000000000001024. Online ahead of print. doi: 10.1161/CIR.0000000000001024. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Left or Right Transradial Approach? Comparing Radiation Exposure in Coronary Procedures

Radiation exposure during percutaneous procedures is a problem both for patients and operators. The transradial is currently the preferred approach, vs. femoral; however, whether...

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....